QIAGEN has unveiled its latest innovation in next-generation sequencing (NGS)—the QIAseq xHYB Long Read Panels, a new suite of target enrichment solutions specifically developed to enhance long-read sequencing of genomically challenging regions.
This launch marks a significant expansion of QIAGEN’s differentiated NGS portfolio, reinforcing its capability to support both short-read and long-read sequencing platforms. The new panels are fully optimized for native long-read technologies, including platforms from PacBio (NASDAQ: PACB), and are engineered to broaden the detection range of genomic variation—enabling high-resolution applications such as HLA typing, repeat expansion analysis, and structural variant detection, areas traditionally difficult for short-read sequencing technologies.
“This launch is a key milestone in our genomics roadmap and underscores our commitment to supporting high-impact science,” said Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN. “We continue to invest in solutions that push the boundaries of genomic discovery in areas like immune profiling, complex disease genetics, and oncology. Our aim is to deliver not only deeper insights but also accelerate their translation into future clinical applications.” David Miller, Vice President of Global Marketing at PacBio, added: “We’re thrilled to deepen our partnership with QIAGEN as demand grows for high-resolution sequencing. With the adoption of our HiFi-powered benchtop sequencer, Vega, researchers are achieving unprecedented accuracy and long-read capabilities, unlocking new frontiers in clinical and translational research.”
Exceptional Target Completeness and Uniformity: Reliable performance across complex genomic regions
Flexible Panel Options: Includes ready-to-use panels for hereditary cancer and HLA typing, plus customizable formats
Optimized for Long DNA Fragments: Fully compatible with high-molecular-weight DNA extraction kits
Integrated Bioinformatics: Seamless analysis through QIAGEN Digital Insights for fast, accurate interpretation
Long-read sequencing is gaining significant traction in translational and clinical genomics, offering enhanced capabilities for haplotype phasing, repeat region characterization, and structural variant resolution. Unlike synthetic or stitched-read approaches, native long-read sequencing provides a more comprehensive view of complex regions—critical for advancing precision medicine.
With the launch of the QIAseq xHYB Long Read Panels, QIAGEN now offers one of the most complete NGS solutions on the market. Researchers can choose between short-read, long-read, or integrated hybrid approaches depending on their sample type and study goals.
QIAGEN’s end-to-end NGS ecosystem—spanning sample extraction, target enrichment, library preparation, automated QC, and advanced bioinformatics—supports a wide array of applications including whole genome, exome, transcriptome, targeted, and RNA sequencing. These tools are compatible with leading sequencing platforms and serve researchers across academic, clinical, and biopharma settings.